The effects of Qishenyiqi dripping pill on cardiac remodeling in patients with chronic stable heart failure have not been reported. This project aims to clarify the efficacy and safety of Qishenyiqi in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure after myocardial infarction were selected and randomly divided into two groups: the treatment group was treated with Qishenyiqi dripping pills; The control group was given placebo treatment. After 12 months of follow-up, the effects of Qishenyiqi on cardiac remodeling and function and cardiovascular adverse events were evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
210
Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Placebo, 1 bag once, three times a day, 12 months
Panpan Hao
Jinan, Shandong, China
Qianfoshan Hospital, Shandong University
Jinan, Shandong, China
Jinan Central Hospital Affiliated to Shandong First Medical University
Jinan, China
LVEDVI=LVEDV/BSA
Changes of left ventricular end-diastolic volume index (LVEDVI) compared with baseline after 12 months
Time frame: From baseline to 12 months after follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.